DSLT demonstrates a ≥ 20% reduction of IOP from pre-treatment baseline in POAG patients naïve of previous glaucoma treatment at 12 months.
Primary open angle glaucoma
Patients age 30 or greater with an IOP of 18-26 mmHg
Mild to moderate POAG patients (mild or moderate according to the AAO PPP Guidelines)
DSLT procedure
History of prior glaucoma treatment - this includes past medication use (in either eye), previous lasers or incisional surgery
Angle closure patients
Ocular Hypertension
Baseline VF MD of worse than -12dB
55 Treatment naïve (including medication in either eye, previous laser or surgery) mild to moderate POAG subjects
Cohort
Prospective
DSLT enables newly diagnosed patients to remain well controlled and off medications
DeviceDSLT enables newly diagnosed patients to remain well controlled and off medications
Success of IOP Reduction Through DSLT Utilization
Proportion of patients (%) with DSLT success as defined as IOP lowering of \>20% and no additional medications or procedures at 12 months.
Other Improvements to Disease State through DSLT Treatment
• Change in mean deviation.. (dB)
Other Improvements to Disease State through DSLT Treatment
• Change in RNFL /GCA (µm)
Other Improvements to Disease State through DSLT Treatment
• Overall IOP reduction (mmHG)
Other Improvements to Disease State through DSLT Treatment
• Medication reduction (#0-5)
Click on the lead sponsor to view all of their trials.
Barnet Dulaney Perkins Eye Centers
Lead sponsor
Alcon, a Novartis Company
Collaborator
